Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Clinical Study of Maintenance Therapy with immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line Therapy

Trial Profile

Randomized Clinical Study of Maintenance Therapy with immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lefitolimod (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms IMPULSE
  • Sponsors Mologen
  • Most Recent Events

    • 20 Aug 2018 Results published in the Annals of Oncology
    • 06 Apr 2018 Results published in a Mologen Media Release.
    • 04 Jan 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top